In the past 20 years, SHP2 has been reported to participate in developmental diseases, such as Noonan syndrome, metachondromatosis, and malignancies such as juvenile myelomonocytic leukemia (Zhang et al., 2015). Here, PTPN11 is linked to Noonan syndrome.